Teva's Biaxin XL Generic Would Irreparably Harm Abbott, Court Rules
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva is preliminarily enjoined from launching extended-release clarithromycin pending a ruling on the merits of patent infringement claims. A Chicago federal judge preliminarily rules that only one of three Abbott patents at issue is valid. Teva expects to file an expedited appeal to the Federal Circuit.